IGM Biosciences
IGMS
IGMS was delisted on the 13th of August, 2025.
81 hedge funds and large institutions have $1.02B invested in IGM Biosciences in 2020 Q2 according to their latest regulatory filings, with 25 funds opening new positions, 38 increasing their positions, 11 reducing their positions, and 6 closing their positions.
317% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 6
245% more repeat investments, than reductions
Existing positions increased: 38 | Existing positions reduced: 11
38% more capital invested
Capital invested by funds: $742M → $1.02B (+$281M)
31% more funds holding
Funds holding: 62 → 81 (+19)
2.89% more ownership
Funds ownership: 55% → 57.9% (+2.9%)
67% less funds holding in top 10
Funds holding in top 10: 3 → 1 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Alkeon Capital Management
New York
|
+$16.4M |
| 2 |
PAMU
Pictet Asset Management (UK)
London,
United Kingdom
|
+$14.8M |
| 3 |
State Street
Boston,
Massachusetts
|
+$13.3M |
| 4 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
+$8.28M |
| 5 |
BlackRock
New York
|
+$6.61M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
United Kingdom
|
-$33.5M |
| 2 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$5.22M |
| 3 |
LGM
Logos Global Management
San Francisco,
California
|
-$4.98M |
| 4 |
VC
Vivo Capital
Palo Alto,
California
|
-$4.87M |
| 5 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$2.86M |
IGMS Hedge Fund Activity: Q2 2020 in Review
81 of the 4,878 institutional investors tracked by Wall St. Rank reported a position in IGM Biosciences (IGMS) for Q2 2020, worth a combined $1.02B — up 38% from $742M a quarter earlier.
Buyers outnumbered sellers: 25 funds opened new IGMS positions and 6 closed out — a net gain of 19 holders — while 38 added to existing stakes and 11 trimmed.
The largest buyer was Alkeon Capital Management, adding an estimated $16.4M. The largest seller was Janus Henderson Group, cutting an estimated $33.5M.
- 81 institutional investors held IGM Biosciences (IGMS) as of Q2 2020, up from 62 in Q1 2020.
- Funds reported $1.02B of IGM Biosciences stock for Q2 2020, up 38% quarter-over-quarter.
- 25 funds opened new IGM Biosciences positions in Q2 2020 and 6 closed out, a net change of +19 holders.
- The largest IGM Biosciences buyer in Q2 2020 was Alkeon Capital Management, an estimated $16.4M added.
- The largest IGM Biosciences seller in Q2 2020 was Janus Henderson Group, an estimated $33.5M sold.
Based on aggregated 13F filings for Q2 2020.